Free Trial
NASDAQ:SLN

Silence Therapeutics (SLN) Stock Price, News & Analysis

Silence Therapeutics logo
$5.54 -0.15 (-2.64%)
As of 07/3/2025 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Silence Therapeutics Stock (NASDAQ:SLN)

Key Stats

Today's Range
$5.52
$5.79
50-Day Range
$3.40
$6.05
52-Week Range
$1.97
$22.47
Volume
26,195 shs
Average Volume
299,488 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.83
Consensus Rating
Moderate Buy

Company Overview

Silence Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

SLN MarketRank™: 

Silence Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Silence Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Silence Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Silence Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Silence Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Silence Therapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Silence Therapeutics is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Silence Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Silence Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Silence Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Silence Therapeutics has recently decreased by 9.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Silence Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Silence Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Silence Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Silence Therapeutics has recently decreased by 9.95%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Silence Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Silence Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Silence Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Silence Therapeutics' insider trading history.
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Silence Therapeutics plc GAAP EPS of -C$0.20
See More Headlines

SLN Stock Analysis - Frequently Asked Questions

Silence Therapeutics' stock was trading at $6.88 at the beginning of the year. Since then, SLN stock has decreased by 19.5% and is now trading at $5.54.

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.42. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative net margin of 260.55% and a negative trailing twelve-month return on equity of 56.17%.

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
5/08/2025
Today
7/06/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLN
Fax
N/A
Employees
100
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$33.83
High Stock Price Target
$75.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+510.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.31 million
Net Margins
-260.55%
Pretax Margin
-257.17%

Debt

Sales & Book Value

Annual Sales
$43.26 million
Price / Cash Flow
N/A
Book Value
$4.48 per share
Price / Book
1.24

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.39

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:SLN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners